All Updates

All Updates

icon
Filter
Partnerships
Foundation Medicine partners with Repare Therapeutics to support oncology clinical trials and diagnostics development
Precision Medicine
Jun 12, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 12, 2024

Foundation Medicine partners with Repare Therapeutics to support oncology clinical trials and diagnostics development

Partnerships

  • Foundation Medicine has partnered with Repare Therapeutics to offer genomic profiling for patients participating in Repare's ongoing MYTHIC study involving the Lunresertib drug.

  • The collaboration aims to use FoundationOneCDx, a comprehensive genomic profiling test, as a potential companion diagnostic for the Lunresertib program. Lunresertib is currently being assessed individually and in combination in several studies across Europe and North America. The partnership seeks to use and advance diagnostics in cancer treatment, especially in cases with complex biomarkers and high unmet needs. 

  • Foundation Medicine specializes in comprehensive genomic profiling for cancer treatment. The company provides clinical diagnostic tests that analyze cancer’s genetic alterations, enabling personalized treatment plans. Its key products include FoundationOneCDx, FoundationOneLiquid CDx for blood-based cancers, and FoundationOneHeme for hematologic malignancies. ​

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.